These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18998217)

  • 1. The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study.
    Yildirim S; Bolkent S; Sundler F
    J Mol Histol; 2008 Dec; 39(6):635-42. PubMed ID: 18998217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ghrelin and insulin gene expression changes in streptozotocin-induced diabetic rats after rosiglitazone pretreatment.
    Yildirim S; Sundler F; Bolkent S
    Eur J Histochem; 2007; 51(1):11-8. PubMed ID: 17548264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.
    Lin CY; Gurlo T; Haataja L; Hsueh WA; Butler PC
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6678-86. PubMed ID: 16204373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Protective effect of rosiglitazone sodium on islet beta-cell of STZ induced diabetic rats through JNK pathway].
    Liu GY; An ZM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):430-4. PubMed ID: 19626998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing islet engraftment with rosiglitazone.
    Hsu BR; Fu SH; Ku KW; Yang TY; Juang JH; Chen ST
    Transplant Proc; 2005; 37(1):245-7. PubMed ID: 15808609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative histopathological assessment of retardation of islets of langerhans degeneration in rosiglitazone-dosed obese ZDF rats using combined insulin and collagens (I and III) immunohistochemistry with automated image analysis and statistical modeling.
    Jones HB; Bigley AL; Pemberton J; Randall KJ
    Toxicol Pathol; 2013; 41(3):425-44. PubMed ID: 23047688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide.
    Udayasankar J; Zraika S; Aston-Mourney K; Subramanian SL; Brooks-Worrell BM; Taborsky GJ; Hull RL
    Transplant Proc; 2013 Mar; 45(2):574-9. PubMed ID: 23267797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
    Guo Z; Qin Z; Zhang R; Li J; Yin Y
    Eur J Pharmacol; 2012 Jun; 685(1-3):116-25. PubMed ID: 22542658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
    Abou Daya K; Abu Daya H; Nasser Eddine M; Nahhas G; Nuwayri-Salti N
    J Diabetes; 2015 Jan; 7(1):85-94. PubMed ID: 24548695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
    Buckingham RE; Al-Barazanji KA; Toseland CD; Slaughter M; Connor SC; West A; Bond B; Turner NC; Clapham JC
    Diabetes; 1998 Aug; 47(8):1326-34. PubMed ID: 9703335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
    Brooks-Worrell BM; Palmer JP
    Clin Exp Immunol; 2013 Feb; 171(2):164-70. PubMed ID: 23286943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.
    Yoon SY; Park JS; Choi JE; Choi JM; Lee WJ; Kim SW; Kim DH
    Neurobiol Dis; 2010 Nov; 40(2):449-55. PubMed ID: 20655383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
    Ghanaat-Pour H; Sjöholm A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
    Kaya-Dagistanli F; Ozturk M
    Acta Histochem; 2013 Jul; 115(6):577-86. PubMed ID: 23351716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
    Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
    Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.